Weathered boatStoke Therapeutics $STOK
Grew revenue 405% in FY2025 to $184 million, operating margin -11.2% against a -3.8% median for pharmaceutical preparations, equity 84.2% of assets.
Last filing10-Q, 3 Nov 2026
Edgarette’s full reading · exposure, experience, soundness, credibility, range
🫧 Edgar looked up Stoke Therapeutics, Inc. ($STOK). Last filing: 10-Q, 2026-11-03. 13 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2026-03-27.
🔖 Exposure: revenue $184.4M (FY2025). Experience: revenue up 404.5% on the year, up 145.8% a year over 3 years; operating margin -11.2%, up from -277.3%. Soundness: equity 84.2% of assets, return on equity -2.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $573.7M and $802.2M next year (method v4.1: its own 1-year record of growth weighed at 0% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $527.1M to $876.2M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -11.2% against a -3.8% median; growth 404.5% against 13.7%.
Read from its own SEC filings · nothing written, nothing inferred
Speed and cash · fiscal 2025
| Cash flow (op · inv · fin · free) | $46M · −$187M · $97M · $45M |
| Investment book (cash · short · long) | $84M · $200M · $106M · current ratio 5.28 · unrealized $1M |
| Revenue swing · equity of assets | — · 84.2% |
The figures, as filed
| Fiscal year end | 2025-12-31 |
| Revenue | $184M |
| Revenue, on the year | 404.5% |
| Revenue, a year over the record | 145.8% |
| Operating margin | −11.2% |
| Operating margin, prior year | −277.3% |
| Net margin | −3.7% |
| Research and development | $138M · 74.8% of revenue |
| Total debt | — |
| Equity of assets | 84.2% |
| Return on equity | −2.0% |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $-0.12 |
| Book value per share | $5.95 |
| Revenue per share | $3.11 |
| Shares outstanding | 59,219,184 |
| Audited years read | 4 |
Peers: the median of 114 filers with $50M+ revenue in pharmaceutical preparations.
Classic signals · fiscal 2025Altman Z″ 5.29 safe zone 1968Piotroski F 5 of 9 middling 2000Beneish M not enough filed detail (needs receivables, cost of revenue, PP&E, depreciation, SG&A for two years)Sloan accruals -15.2% earnings backed by cash 1996DuPont ROE -2.4% = margin -3.7% × turns 0.53 × leverage 1.19
What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →
Health HarborStoke Therapeutics sails as: Weathered boat
Health watch · 12 monthsAuditor changeDirector or officer change ×3
Sailing speed follows growth: 145.9% a year crosses the harbor in 30 seconds.
🌊 Visit the Bay →- filed auditor change in the last 12 months
- operating loss: a margin of -11.2% in FY2025
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
- 10-Q · 2026-11-03
- 8-K · 2026-10-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits
- 8-K · 2026-09-25 · 5.02 Departure or Election of Directors; Appointment of Officers
- 8-K · 2026-08-03 · 8.01 Other Events; 9.01 Financial Statements and Exhibits
- 10-Q · 2026-08-03
- 8-K · 2026-08-03 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits
Measured, not prophesiedSuccess tools: score it, compare it, see its fieldFour questions. Scored against the SEC filings of the companies in your field.
Each benchmark is the median of SEC filers in your industry code, from their own audited filings, read on the filing boards. Reporting, not investment advice.
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · Open in Excel (CSV) · Ten-year table (CSV) ·